Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. Elsaka R, Kitagwa JM, Refaat T, Mahmoud AA, et al. Am J Clin Oncol 2023 Feb 3. doi: 10.1097/COC.0000000000000983.

Read + Share

Amedeo Smart

Independent Medical Education

Elsaka R, Kitagwa JM, Refaat T, Mahmoud AA, et al. Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. Am J Clin Oncol 2023 Feb 3. doi: 10.1097/COC.0000000000000983.
PMID: 36735492